Evaxion today announced that the U.S. Food and Drug Administration (“FDA”) determined that the Company may proceed with its Phase 2b clinical trial of EVX-01.

Evaxion today announced that they expect to present data from their two clinical trials of personalized cancer immunotherapies (cancer vaccines) EVX-01 and EVX-02 in the second quarter of 2023.

Evaxion has signed a Vaccine Discovery Collaboration Agreement with ExpreS²ion Biotech for the joint development of a novel cytomegalovirus (CMV) vaccine candidate

Evaxion announced today promising clinical data from the Phase 1/2a first-in-human study of its DNA-based cancer immunotherapy, EVX-02.

Evaxion announced today its third quarter 2022 financial results and provided an operational and business update

Evaxion today announced that it intends to further increase its focus on its lead oncology assets EVX-01 and EVX-02/03 to bring them to clinical proof of concept followed by out-licensing. The Company further plans preclinical partnering of its early-stage programs under its infectious disease platforms.

Evaxion announces that its new Chief Executive Officer (CEO) Per Norlén has joined the company on October 1^st.

In the company’s first phase 2b clinical trial, Evaxion is evaluating the efficacy and safety of EVX-01 in adults with metastatic melanoma. The trial is being conducted globally at clinical sites across the US, Europe, and Australia in collaboration with Merck & Co., Inc., which is supplying the trial with its PD-1 inhibitor, KEYTRUDA^®.

Evaxion announced that the Company, in collaboration with UMass Chan Medical School (“UMass Chan”), has received a grant from the U.S. National Institutes of Health (“NIH”) for the development of a gonorrhea lead vaccine candidate.